Brief: PYC Therapeutics Says Safety Review Committee Approves Dose Escalation To Patient Cohort
22/09/2023 03:31
Sept 22 (Reuters) - PYC Therapeutics Ltd PYC.AX :
* SAFETY REVIEW COMMITTEE APPROVES DOSE ESCALATION TO
PATIENT
COHORT
Source text for Eikon: ID:nASX8jdHwv
Further company coverage: PYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director